Denosumab - Biologic Drug Details

Summary for denosumab

Tradenames:	2
High Confidence Patents:	10
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for denosumab

Recent Clinical Trials for denosumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Taiwan University Hospital, Yun-Lin Branch	PHASE4
Peking Union Medical College Hospital	NA
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	PHASE1

See all denosumab clinical trials

Pharmacology for denosumab

Mechanism of Action	RANK Ligand Blocking Activity
Established Pharmacologic Class	RANK Ligand Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for denosumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for denosumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320		2035-12-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2038-07-18	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2034-12-09	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2035-05-13	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320		2039-01-29	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for denosumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320		2033-06-06	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2036-12-20	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2031-10-05	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2037-05-22	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320		2035-07-16	Patent claims search

International Patents for denosumab

Country	Patent Number	Estimated Expiration
Australia	2008261137
Slovenia	0975754
World Intellectual Property Organization (WIPO)	2018200918
South Korea	20010006405
World Intellectual Property Organization (WIPO)	2012145682

Supplementary Protection Certificates for denosumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C00951551/01	Switzerland		PRODUCT NAME: DENOSUMABUM; REGISTRATION NO/DATE: SWISSMEDIC 60210 03.08.2010
1090038-9.L	Sweden		PRODUCT NAME: DENOSUMAB; REG. NO/DATE: EU/1/10/618/001 20100526
44/2010	Austria		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
300467	Netherlands		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100528
45/2010	Austria		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 MITTEILUNG 20100528

Denosumab Market Dynamics and Financial Trajectory: Sales Drivers, Patent/Exclusivity Timelines, Biosimilar Risk, and Revenue Outlook

Last updated: May 17, 2026

Denosumab (brand: Xgeva for bone metastases and giant cell tumor; Prolia for osteoporosis) has delivered large global revenues built on: (1) high switching barriers from oncology and bone-protection protocols, (2) durable payer acceptance for fracture prevention and skeletal-related-event risk reduction, and (3) long-duration dosing (60–120 mg every 4 weeks or every 6 months depending on indication). Financial trajectory is increasingly shaped by patent/exclusivity expiry windows, biosimilar launch timing, and label strategy (denosumab vs zoledronic acid; sequencing in metastatic castration-resistant prostate cancer and other settings).

The market is now in a late-cycle phase in multiple geographies due to biosimilar approvals and launches, with the competitive impact strongest in markets where biologic interchange and procurement tools (tendering, formulary preference) are mature. Ongoing dynamics come from indication expansion, real-world adherence, and expanded use in settings with limited alternatives.

---

How much has denosumab earned and what is the revenue trajectory by indication?

Denosumab revenues are concentrated across two FDA-approved brands that map to distinct payer decision paths and pricing pressure profiles.

Indication split that drives revenue mix

• Prolia (denosumab): osteoporosis (postmenopausal women at high fracture risk; men with osteoporosis at high fracture risk; glucocorticoid-induced osteoporosis in certain patients; aromatase inhibitor–associated bone loss; advanced prostate cancer on androgen deprivation therapy).
• Xgeva (denosumab): oncology bone disease (to prevent skeletal-related events in patients with bone metastases from solid tumors; treatment of giant cell tumor of bone; treatment of hypercalcemia of malignancy).

Financial trajectory: late-cycle pattern

Across the branded life cycle, denosumab typically shows:

• Early to mid-cycle growth driven by uptake and guideline incorporation in osteoporosis and bone metastasis care pathways.
• Mature peak-to-decline dynamics when biosimilar availability increases and procurement pressure shifts from clinical preference to cost-based contracting.

What matters to a revenue forecast

• Volume: continuity of dosing schedules and persistence in osteoporosis clinics and oncology infusion pathways.
• Net price: country tendering, hospital contracting, payer rebate pressure post-biosimilar entry.
• Mix: proportion of Xgeva vs Prolia in the total portfolio shifts as oncology penetration and payer constraints change.
• Substitution constraints: where switching rules and physician behavior create slower uptake of biosimilars.

---

What market drivers have supported denosumab sales and uptake through late-cycle?

Bone protection and skeletal-related event reduction in oncology

For Xgeva, clinical utility centers on reducing skeletal-related events (SREs) in metastatic bone disease versus standard comparator regimens. This creates:

• Protocol pull-through in oncology practices.
• Reduced opportunity for competitive substitution once treatment pathways are established.

Osteoporosis adherence to long-interval dosing

Prolia’s dosing interval (typically every 6 months) supports:

• Lower clinic resource burden versus more frequent oral or infusion schedules.
• Higher adherence in real-world settings, which matters for persistence-based revenue stability.

Guideline placement and payer acceptance

Denosumab’s entrenched guideline role reduces barrier to coverage. Payer plans tend to prefer drugs with:

• Clear evidence for fracture reduction outcomes.
• Predictable monitoring and administration workflows.

---

When do denosumab patents and exclusivity expire and how does that affect the financial curve?

Denosumab is subject to layered IP: composition, formulation, device/manufacturing, and method-of-use patents, plus biologics exclusivity frameworks. Expiry impacts are not uniform across geographies because biosimilar pathways and regulatory holdings run in parallel with patent litigation outcomes.

Key commercial implication

• Revenue usually bends at the first credible biosimilar entry window in a given country, with a second bend tied to expanded biosimilar catalog breadth and stronger contracting.
• Where litigation delays are used, the curve shows stepwise declines rather than smooth year-over-year erosion.

Patent estate structure that shapes “stepwise” revenue loss

• Product-level exclusivity: deters direct biosimilar entry until key legal triggers clear.
• Method-of-use exclusivity/patents: can preserve branded share in particular indications even after baseline biosimilar entry for the core product.
• Formulation/manufacturing patents: can block specific development approaches or trigger settlements on narrow scopes.

(A complete, jurisdiction-by-jurisdiction patent expiration schedule requires an Orange Book and patent-lists pull for each brand and each relevant biosimilar entry case. The market-wide impacts below reflect observed dynamics in later-stage biologic markets.)

---

What biosimilar and generic entry risks exist for denosumab, and which launch waves matter most?

Denosumab is a biologic. The primary competitive threat is biosimilar entry, not small-molecule generic substitution.

Biosimilar risk factors that determine how quickly sales fall

1. Interchangeability and switching rules (country and payer dependent).
2. Physician trust and clinical comfort with biosimilars post-approval.
3. Tendering mechanics (single-source vs multi-source procurement).
4. Volume commitments and hospital formularies shifting after biosimilars become available.
5. Distribution and patient support programs (brand retention vs conversion programs).

The “first biosimilar” effect

The first biosimilar typically produces:

• Faster net price pressure in tenders.
• Slower absolute volume loss if clinicians resist switching.
• Then cumulative share erosion as second and third biosimilars enter and contracting tightens.

The “catalog breadth” effect

As more biosimilars reach coverage:

• Payers expand their negotiating leverage.
• Formularies may move from tiered preference to outright substitution depending on tender outcomes.

---

What is the Orange Book and FDA regulatory status relevance for denosumab and its biosimilar competition?

For biologics like denosumab, the FDA’s key system for protein drug biosimilar and exclusivity tracking differs from the Orange Book used for small molecules.

How FDA regulatory events affect market timing

Market timing tracks:

• Biosimilar approval dates.
• Post-marketing commitments and label scope.
• Exclusivity and patent dispute outcomes that affect launch authorization.

Commercial effect pathway

Even after regulatory approval:

• Launch timing may be delayed by patent litigation.
• Payer uptake lags approval because formularies and tender cycles can run 6 to 18 months behind.

---

How do biosimilar label scopes for denosumab differ from the reference products?

Biosimilar label scope can reduce or preserve competition depending on:

• Indication coverage and extrapolation.
• Patient population exclusions or remaining label restrictions driven by reference product interpretation.
• Substitution language (country-specific) and tender policy.

Revenue preservation can persist via indication-specific protection

Even with biosimilar access for an instrumented product label, remaining patent or exclusivity barriers can:

• Protect high-margin indications temporarily.
• Limit biosimilar use in oncology settings where governance is tighter.

---

How does denosumab compare with zoledronic acid and other bone-modifying agents on market dynamics?

Switching friction in oncology and osteoporosis

• Denosumab’s dosing convenience (and oncology protocol integration) supports sustained utilization even when comparators are cheaper.
• Zoledronic acid’s adverse event profile and administration intensity can create physician preference that limits pure price-led substitution.

Competitive procurement dynamics

When biosimilars enter, procurement tends to move toward:

• Multi-source tenders including biosimilar denosumab and generic/low-cost bisphosphonates.
• Where denosumab biosimilars price below brand, the market shifts rapidly toward lowest net cost for the same therapeutic pathway.

---

Which companies are positioned to compete against denosumab and how does that shape pricing power?

Competitive structure in biologic markets typically drives:

• Pricing compression after multiple biosimilar launches.
• Contract-based net price volatility rather than list price declines.

What to look for in competitive positioning

• Portfolio breadth across oncology and osteoporosis indications.
• Distribution reach and hospital contracting capability.
• Evidence packages supporting extrapolation comfort with prescribers.

---

What patent litigation affects denosumab biosimilar launches and settlement-driven market access?

Biologic patent disputes often produce:

• Delayed launches after Paragraph IV-style challenges for small molecules, and analogous biosimilar patent dispute systems for biologics.
• Settlement terms that can allocate market timing and restrict early launch tactics.

How settlements translate into revenue outcomes

• Settlement can preserve brand share by delaying biosimilar introduction in the most economically valuable indication first.
• Alternatively, settlement can allow early entry with narrow scope, causing targeted price pressure while volumes remain comparatively stable.

---

Formulation and delivery patents: do they create meaningful barriers beyond the main biologic?

Denosumab’s administration is fixed at a clinical level, but packaging, concentration, dosing device presentation, and manufacturing process controls can create:

• Development and scale-up complexity.
• Additional patent thickets that affect launch timing.

Market impact

In practice, the market barrier is less about “device patents” and more about:

• Patent thickets that delay biosimilar approval or launch.
• Manufacturing scale-readiness affecting ability to meet early demand in oncology clinics.

---

What is the country-by-country revenue exposure risk from biosimilar penetration?

Denosumab’s geography matters because:

• Biosimilar regulatory readiness and manufacturing capacity differ.
• Tender systems and interchange policies differ.
• Government reimbursement policies determine speed of uptake.

High-risk profiles

• Markets with mature biosimilar procurement policies and faster tender replacement schedules typically see earlier net price pressure.
• Markets with physician-driven prescribing controls and conservative hospital formulary processes tend to show slower share erosion.

---

What does a realistic financial model for denosumab look like under biosimilar entry scenarios?

Because denosumab is in a multi-brand, multi-indication context, a scenario model should track:

• Base-case: limited price erosion post-first biosimilar due to persistence and slow switching.
• Downside: multiple biosimilar entries plus aggressive tendering lead to faster net price compression and share losses.
• Upside: label expansions, stronger persistence, and delayed biosimilar breadth keep branded share higher longer.

Model drivers to anchor

• Share loss rate per biosimilar entrant.
• Net price decline per tender cycle.
• Indication-specific retention (Prolia vs Xgeva).
• Volume elasticity: oncology is typically less elastic than osteoporosis once treatment is established.

---

Key Takeaways

• Denosumab’s revenue strength historically came from clinical value in bone disease and dosing convenience that supports persistence in both osteoporosis and oncology bone metastasis settings.
• The financial curve increasingly depends on biosimilar entry timing, tender behavior, and the breadth of biosimilar label coverage across Prolia and Xgeva.
• Revenue erosion is typically stepwise: first net price pressure, then share loss as additional biosimilar entrants increase payer leverage.
• Litigation and settlement outcomes determine the calendar of market access, often creating delayed but abrupt revenue shifts.
• Country-specific procurement and switching rules control speed of biosimilar adoption and therefore the severity of net price compression.

---

FAQs

1) How quickly do denosumab biosimilars typically capture share after first launch?

Share capture depends on tender mechanics, interchange rules, and clinical switching behavior, with the fastest uptake usually occurring in tenders that bundle multiple hospitals and standardize prescribing protocols.

2) Does biosimilar entry impact Prolia (osteoporosis) faster than Xgeva (oncology)?

Often Prolia can face quicker payer-driven substitution in osteoporosis channels, while oncology prescribing governance can slow initial conversion, though this varies by payer contracting.

3) Can denosumab maintain revenue if biosimilar competition appears but indication coverage is limited?

Yes, limited label scope or indication-level patent protection can preserve branded share in protected settings, pushing competition into narrower segments first.

4) What is the biggest financial lever: price or volume?

Net price compression is usually the first visible lever, with volume loss accelerating as prescribing and contracting switch more fully toward biosimilars.

5) What factors most influence investor expectations for denosumab after exclusivity expiry?

The timing of biosimilar breadth, number of entrants in major geographies, expected contracting intensity, and any litigation-driven launch delays.

---

References

No sources were cited.